Sorafenib-induced destructive thyroiditis, Thyroid, vol.20, issue.9, pp.1043-1047, 2010. ,
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma, Thyroid, vol.21, issue.2, pp.197-202, 2011. ,
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma, Clin Endocrinol (Oxf), vol.69, issue.4, pp.669-72, 2008. ,
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib, Ann Oncol, vol.19, issue.2, pp.265-273, 2008. ,
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation, Urol Oncol, vol.28, issue.5, pp.515-524, 2010. ,
Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer, Endocrine, vol.42, issue.3, pp.756-763, 2012. ,
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosomepositive chronic myeloid leukemia, Thyroid, vol.20, issue.11, pp.1209-1223, 2010. ,
Imatinib induces hypothyroidism in patients receiving levothyroxine, Clin Pharmacol Ther, vol.78, issue.4, pp.433-441, 2005. ,
A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma, J Clin Endocrinol Metab, vol.92, issue.9, pp.3466-3475, 2007. ,
Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report, Chemotherapy, vol.58, issue.2, pp.142-147, 2012. ,
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors, Ann Intern Med, vol.145, issue.9, pp.660-664, 2006. ,
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, vol.99, issue.1, pp.81-84, 2007. ,
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake, J Clin Endocrinol Metab, vol.92, issue.9, pp.3531-3535, 2007. ,
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review, Eur J Endocrinol, vol.160, issue.3, pp.331-337, 2009. ,
Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib, Thyroid, vol.23, issue.4, pp.443-451, 2013. ,
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma, Jpn J Clin Oncol, vol.42, issue.8, pp.742-749, 2012. ,
Motesanib diphosphate in progressive differentiated thyroid cancer, N Engl J Med, vol.359, issue.1, pp.31-42, 2008. ,
Imatinib: the narrow line between immune tolerance and activation, Trends Mol Med, vol.11, issue.9, pp.397-402, 2005. ,
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update, Cytotherapy, vol.10, issue.6, pp.633-674, 2008. ,
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors, Trends Mol Med, vol.16, issue.4, pp.184-92, 2010. ,
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?, Thyroid, vol.25, p.11, 2015. ,